Ginkgo Bioworks
Ginkgo Bioworks' revenue fell 25.1% to $170 million in fiscal 2025. Its operating margin was −185.3%, up from −246.5% a year earlier. Free cash flow was −$179 million. The diluted share count rose 6.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ginkgo Bioworks does
Ginkgo Bioworks sells research services that help customers engineer living cells, for example to make medicines, crops or industrial products. It does not make end products itself. Its stated mission is to make biology easier to engineer.
It has two business segments. Cell engineering provides tools and biological research services to drug, farm and industrial companies and to governments. Biosecurity provides services to customers who want to identify, monitor and prevent biological threats. Its customers include government and commercial customers. In 2024 it added a tools offering, where customers run some of the research themselves using Ginkgo's data generation, automation and AI tools.
Ginkgo says its Autonomous Lab, a flexible lab built from automated carts, and its reusable data assets let it improve its services with each project. It has also taken equity stakes in other companies it works with.
Its biggest risks, as it describes them
- It may need a lot more capital to fund its business.
- It has gone through major organizational change, which it may not manage well.
- Demand for its biosecurity services is uncertain.
- It may fail to win and keep customers for its cell engineering services and tools.
- It holds shares in other companies, which can be volatile or hard to sell.
Income statement
Ginkgo Bioworks lost money in fiscal 2025: a net loss of $313 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,550 | 1,316 | 944 | 562 | 423 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −770.5x | −20,839.2x | −9,294.7x | −5,954.9x | — |
| Current ratio | 12.8x | 8.4x | 6.1x | 5.6x | 4.9x |
| Quick ratio | 12.8x | 8.4x | 6.1x | 5.6x | 4.9x |
Cash flow
Projections
Project Ginkgo Bioworks' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Ginkgo Bioworks says to expect
- Full year 2026: cash burn
Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.
Insider trades
No officer, director or 10% owner of Ginkgo Bioworks reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −181.1% | −178.0% | −130.1% |
| Altman Z'' | −8.52 | −13.05 | −16.72 |
| Accruals ratio | −28.4% | −14.9% | −11.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | — | — |
Compare
Put Ginkgo Bioworks side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | |
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | Compare |
| PacBio | FY25 | 3.9% | −346.1% | −71.2% | −77.1% | — | 3 | Compare |
| Maravai LifeSciences | FY25 | −28.3% | −115.9% | −38.1% | −32.0% | — | 2 | Compare |
| Cytek Biosciences | FY25 | 0.5% | −20.0% | −4.3% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 54 | 77 | 314 | 478 | 252 | 227 | 170 |
| Revenue growth | — | 41.5% | 309.4% | 52.2% | −47.4% | −9.7% | −25.1% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 96 | 160 | 1,150 | 1,053 | 581 | 424 | 244 |
| Operating income | −72 | −137 | −1,828 | −2,209 | −864 | −560 | −315 |
| Net income | −119 | −127 | −1,830 | −2,105 | −893 | −547 | −313 |
| Diluted EPS (US$) | −4.00 | −4.00 | −55.60 | −50.20 | −18.37 | −10.54 | −5.64 |
| Diluted shares (millions) | 29 | 32 | 34 | 42 | 49 | 52 | 56 |
| Cash flow | |||||||
| Cash from operations | −45 | −136 | −254 | −252 | −296 | −320 | −171 |
| Capital expenditure | 22 | 58 | 56 | 52 | 41 | 62 | 8 |
| Free cash flow | −67 | −194 | −310 | −304 | −336 | −382 | −179 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 25 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 12 | 82 | 0 | 5 | 0 |
| Stock-based compensation | 1 | 0 | 1,606 | 1,931 | 230 | 112 | 82 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 495 | 381 | 1,550 | 1,316 | 944 | 562 | 423 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | — | 675 | 2,071 | 2,539 | 1,665 | 1,377 | 1,120 |
| Total liabilities | — | 205 | 504 | 803 | 568 | 661 | 611 |
| Shareholders' equity | 502 | 461 | 1,505 | 1,736 | 1,097 | 716 | 509 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −132.1% | −178.8% | −582.6% | −462.4% | −343.8% | −246.5% | −185.3% |
| Net margin | −220.2% | −165.2% | −583.1% | −440.6% | −355.1% | −240.9% | −183.8% |
| Free cash flow margin | −123.4% | −252.6% | −98.9% | −63.7% | −133.7% | −168.3% | −105.0% |
| Rule of 40 (growth + FCF margin) | — | −211.1% | 210.5% | −11.5% | −181.1% | −178.0% | −130.1% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | −186.1% | −129.9% | −63.0% | −60.3% | −51.1% |
| Return on assets | — | — | −133.3% | −91.3% | −42.5% | −36.0% | −25.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — |